Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS)
Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases. The
The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK). With this agreement,
The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive
The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib. The global R&D-based biopharmaceutical company’s new drug
The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government. AstraZeneca’s
The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan. A candidate from
California-based biopharmaceutical company Gilead Sciences, Inc. and New Jersey-based Merck have announced their agreement to develop and commercialise the long-acting HIV treatments lenacapavir and islatravir. The treatments combine
Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan. Lanadelumab subcutaneous injection
A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.